BC Extra | Jan 31, 2020
Financial News

Jan. 30 Financial Quick Takes: Vertex, Black Diamond, Alexion, Alector, DBV

Trikafta sales bolster Vertex’s revenue  Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) handily beat consensus estimates with its 4Q19 earnings Thursday, bolstered by the $420 million in sales newly approved CF therapy Trikafta elexacaftor/tezacaftor/ivacaftor brought in during its...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BC Innovations | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
BC Week In Review | Feb 8, 2019
Financial News

Immuno-neurology company Alector dips after $175.8M IPO

Alector Inc. (NASDAQ:ALEC) raised $175.8 million in an IPO to support clinical trials of a handful of antibodies for neurologic indications including frontotemporal dementia and Alzheimer's disease. The immuno-neurology company sold 9.3 million shares at...
BC Extra | Feb 7, 2019
Company News

Immuno-neurology company Alector dips after $175.8M IPO

Alector Inc. (NASDAQ:ALEC) shares fell $1 to $18 Thursday after the company raised $175.8 million in an IPO to support clinical trials of a handful of antibodies for neurologic indications including frontotemporal dementia and Alzheimer's...
BioCentury | Jul 27, 2018
Finance

Manipulating microglia

Alector Inc.’s $133 million series E round provides enough runway for the immuno-neurology and immuno-oncology company to take at least five programs into the clinic in the next two years. Participants in the untranched round,...
BC Week In Review | Jul 27, 2018
Financial News

Alector raises $133M series E

Immuno-neurology and immuno-oncology company Alector Inc. (South San Francisco, Calif.) raised $133 million in a series E round. Participants included new investors Deerfield Management, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia...
BC Extra | Jul 25, 2018
Financial News

Alector raises $133M series E

Immuno-neurology and immuno-oncology company Alector Inc. (South San Francisco, Calif.) raised $133 million in a series E round. Participants included new investors Deerfield Management, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia...
Items per page:
1 - 8 of 8